Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Idea to Innovation

McMaster University

$15,000.00

Market Assessment - Strategic assessment of injectable, in situ gelling materials for ocular drug delivery

FY 2020-21

Summary
Diseases in the eye are becoming increasingly common as the population ages; however, they remain notoriously difficult to treat. For instance, age-related macular degeneration (AMD) affects over 1.4 million Canadians and is the leading cause of vision loss in Canada. While the advent of anti-VEGF agents, a specific class of drugs, has significantly improved the prognosis and outcomes for many of these patients, they require intraocular injections every one to two months to maintain their effectiveness. Similarly, glaucoma, the second leading cause of blindness, requires patients to adhere to a challenging regime of eye drops multiple times each day, causing patients to struggle with compliance. Yet, if these conditions progress to vision loss, patients have been shown to require greater assistance with daily activities, suffer high incidences of depression and anxiety, and have twice the risk of falls; this all results in a substantial decrease in their quality of life. We propose a new delivery system that would work with different therapeutics for a variety of conditions. This would reduce treatments from monthly to bi-annually, increasing both safety and convenience for patients and reducing the burden on the healthcare system. We request funds to complete a Market Assessment to determine which ocular disease condition is best suited to initial development, which will allow us to then create a business plan for successful technology transfer and commercialization.
Program
Idea to Innovation
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
556937-2020
Name nom
Sheardown, Heather
Department département
Chemical Engineering
Organization id
27
Institution établissement
McMaster University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2020
Competition year année de concours
2020
Award amount
15000
Program id
I2IPJ
Program name en
Idea to Innovation
Program name fr
De l'idée à l'innovation
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1902
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical materials
Research subject fr
Matériaux biomédicaux
Installment
inst:1 - 1
Partie
1
Nb partie
1
Application title
Market Assessment - Strategic assessment of injectable, in situ gelling materials for ocular drug delivery
Keyword
NSERC
Application summary
Diseases in the eye are becoming increasingly common as the population ages; however, they remain notoriously difficult to treat. For instance, age-related macular degeneration (AMD) affects over 1.4 million Canadians and is the leading cause of vision loss in Canada. While the advent of anti-VEGF agents, a specific class of drugs, has significantly improved the prognosis and outcomes for many of these patients, they require intraocular injections every one to two months to maintain their effectiveness. Similarly, glaucoma, the second leading cause of blindness, requires patients to adhere to a challenging regime of eye drops multiple times each day, causing patients to struggle with compliance. Yet, if these conditions progress to vision loss, patients have been shown to require greater assistance with daily activities, suffer high incidences of depression and anxiety, and have twice the risk of falls; this all results in a substantial decrease in their quality of life. We propose a new delivery system that would work with different therapeutics for a variety of conditions. This would reduce treatments from monthly to bi-annually, increasing both safety and convenience for patients and reducing the burden on the healthcare system. We request funds to complete a Market Assessment to determine which ocular disease condition is best suited to initial development, which will allow us to then create a business plan for successful technology transfer and commercialization.